Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 27, Issue 8, 2001, Pages 855-861

  Jacobson, P ^a   Park, J J ^b   Defor, T E ^c   Thrall, M ^c   Abel, S ^c   Krivit, W ^c   Peters, C ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Busulfan; Engraftment; Hematopoietic cell transplantation; Hurler syndrome; Inherited metabolic storage disease; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; PHENYTOIN;

ADOLESCENT; ADULT; AGE; ALLOGRAFT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; INFANT; MALE; PRIORITY JOURNAL; SEIZURE; STORAGE DISEASE; TREATMENT FAILURE; WHOLE BODY RADIATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYSOSOMAL STORAGE DISEASES; MALE; METABOLIC CLEARANCE RATE; MUCOPOLYSACCHARIDOSIS I; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 0034987068     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703010     Document Type: Article

References (39)

1. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation
2. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopoly-saccharidosis type VI). Biochemical and clinical status 24 months after transplantation
3. Bone marrow transplantation for the treatment of alpha-mannosidosis
4. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation
5. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation
6. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy
7. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome
8. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children
9. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
10. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
11. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
12. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
13. Up-regulation of glutathione S-transferase activity in enterocytes of young children
14. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi
15. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics (published erratum appears in Bone Marrow Transplant 1996 Oct;18(4):829)
16. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia
17. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation
18. Importance of marrow dose on posttransplant outcome in acute leukemia: Models derived from patients autografted with mafosfamide-purged marrow at a single institution
19. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
20. Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells
21. + cells and progenitor cell recoveries
22. + stem cell augmentation of elutriated allogeneic bone marrow grafts: Results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies
23. Bone marrow graft engineering by counterflow centrifugal elutriation: Results of a phase I-II clinical trial
24. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
25. Non parametric estimation from incomplete observations
26. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
27. Busulfan disposition in children
28. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
29. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
30. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia
31. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells
32. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche
33. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
34. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis
35. Hepatic venoocclusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome
36. Frequency of venoocclusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen
37. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: A meta-analysis
38. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies